Findings

What do systematic reviews say?

4 questions · 4 findings · 1 reviews

Sort:Best matchNewest Highest certainty Download CSV

No studies found 0 · 0%GRADE not reported 0 · 0%Very low 2 · 50%Low 2 · 50%Moderate 0 · 0%High 0 · 0%

Infliximab 5 mg/kg vs infliximab 10 mg/kg

Clinical remission · Patients with active Crohn's disease

It is very uncertain whether infliximab 5 mg/kg changes clinical remission defined as CDAI < 150 at week 4 compared with infliximab 10 mg/kg (very low certainty).

1 finding from 1 review

Infliximab for medical induction of remission in Crohn's disease 2023 · Cochrane Headline outcomes only
RR 1.79 [1.06, 3.02]
1 study · 55 participants
Very low

Infliximab 5 mg/kg vs CT‐P13 biosimilar 5 mg/kg

Clinical remission · Patients with active Crohn's disease

Infliximab 5 mg/kg showed no clear difference in clinical remission defined as CDAI < 150 at week 6 compared with CT‐P13 biosimilar 5 mg/kg (low certainty).

1 finding from 1 review

Infliximab for medical induction of remission in Crohn's disease 2023 · Cochrane Headline outcomes only
RR 0.98 [0.72, 1.32]
1 study · 220 participants
Low

Infliximab 10 mg/kg vs infliximab 20 mg/kg

Clinical remission · Patients with active Crohn's disease

It is very uncertain whether infliximab 10 mg/kg changes clinical remission defined as CDAI < 150 at week 4 compared with infliximab 20 mg/kg (very low certainty).

1 finding from 1 review

Infliximab for medical induction of remission in Crohn's disease 2023 · Cochrane Headline outcomes only
RR 1 [0.52, 1.92]
1 study · 56 participants
Very low

Infliximab 5–10 mg/kg vs placebo

Clinical remission · Patients with active Crohn's disease

Infliximab 5–10 mg/kg may leads to higher clinical remission defined as CDAI < 150 at week 4 compared with placebo (low certainty).

1 finding from 1 review

Infliximab for medical induction of remission in Crohn's disease 2023 · Cochrane Headline outcomes only
RR 4.55 [1.53, 13.5]
1 study · 80 participants
Low